Repligen (NASDAQ:RGEN) Upgraded at Wall Street Zen

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

RGEN has been the subject of a number of other research reports. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. Royal Bank Of Canada reduced their price target on shares of Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. JPMorgan Chase & Co. reduced their target price on shares of Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Finally, Evercore ISI started coverage on shares of Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat, Repligen presently has a consensus rating of "Moderate Buy" and an average target price of $171.46.

Repligen Stock Up 2.7%

RGEN stock traded up $3.24 during midday trading on Friday, hitting $123.35. The company's stock had a trading volume of 941,526 shares, compared to its average volume of 732,460. The firm's 50-day moving average is $128.57 and its 200-day moving average is $141.68. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen has a 12 month low of $102.97 and a 12 month high of $182.52. The company has a market cap of $6.93 billion, a PE ratio of -274.11, a P/E/G ratio of 3.40 and a beta of 1.11.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same period last year, the firm posted $0.28 earnings per share. Repligen's revenue was up 10.4% compared to the same quarter last year. On average, equities research analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Several institutional investors have recently made changes to their positions in the business. Osterweis Capital Management Inc. grew its holdings in Repligen by 18.0% during the 1st quarter. Osterweis Capital Management Inc. now owns 72,765 shares of the biotechnology company's stock valued at $9,259,000 after buying an additional 11,080 shares in the last quarter. Strs Ohio bought a new position in shares of Repligen during the first quarter worth $6,069,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Repligen by 7.3% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 252,497 shares of the biotechnology company's stock valued at $32,128,000 after acquiring an additional 17,154 shares in the last quarter. Woodline Partners LP bought a new stake in Repligen in the 1st quarter valued at $7,152,000. Finally, United Services Automobile Association purchased a new stake in Repligen in the 1st quarter worth $461,000. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.